PolymarketComprobar disponibilidadSin KYC2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
December 31, 68%+1.0pt
Calidad del mercado
67 / 100
Calidad mediaVolumen 24h
1,9 mil €
Liquidez
16,9 mil €
Liquidez mediaCompra / Venta
67.0% / 68.0%
Spread
1.0 pt
Spread estrechoComments
0
Datos de mercado
Actualizado hace 15 minutos
19 ago 26, 17:4931 dic 27, 23:59
Tendencias
Reglas
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
